Grants

01 Jul 2022 - 01 Aug 2022

About 

CS-IRG New Investigator Grant (CS-IRG-NIG) is a sub category of the CS-IRG to cater for new clinical investigators. The CS-IRG-NIG is a step for the new investigator towards winning a first independent national level grant. Applicants with substantial research experience will not be accepted under this category.

Research Themes:

The CS-IRG-NIG is open to application on all research themes. Applications are assessed based on scientific merit and relevance to Singapore, but should prioritisation be required between meritorious applications, the following seven disease areas have been identified as national priorities for research:

  • Cancers and neoplasms
  • Cardiovascular
  • Eye
  • Infection
  • Mental health
  • Metabolic and endocrine
  • Neurological

Evaluation Criteria:

Selection of successful proposals would be based on the following evaluation criteria:

  • Scientific excellence
  • Feasibility of study in local context
  • Productivity
  • Overall impact in local context
  • Suitability of applicant to be an independent investigator and to assume the role of a PI

To be eligible for the CS-IRG-NIG, the following requirements apply:

(i) Awardees of the following grants as PI/Co-PI* at the point of application will not be eligible for the NIG: A*STAR Investigatorship, NRF Fellowship, NMRC CSA and STaR, MOE Tier 2 and 3 grants, MOH/NMRC IRG-equivalent grants^.

*Co-PIs refer to PIs whose projects are jointly led by other PIs (e.g. projects under NMRC’s Bedside & Bench grant). They are not the same as, and should not be confused with Co-Investigators (Co-Is).
^NIC Ageing Grants (with the exception of Health and Longevity Catalyst Awards) are considered IRG-equivalent grants.

(ii) Applicants must not have received external competitive funding exceeding $500,000 (direct costs only), to conduct their own research project as the PI. 

Applicants who are applying under the new investigator category (CS-IRG-NIG) have to work with a mentor for guidance in their research. This mentoring will provide support for a period of supervised research leading eventually to the clinical investigators conducting larger scale research projects independently. Please note that the NIG is intended to fund a new investigator’s independent project, and not to provide additional funding for the mentor's project (or clinical trial). 

Eligibility:

Each CS-IRG-NIG application must be led by a Clinical Principal Investigator (PI) who has to fulfill the eligibility criteria listed below:

  1. PI must be clinically qualified (i.e. with MD/MBBS/BDS) and preferably with post-graduate clinical training and experience.
  2. Allied Health Professionals who meet the following conditions may apply:
    1. Non-medically trained PIs who are nurses, pharmacists or other allied health professions listed on the MOH’s website in clinical practice, doing research in clinical settings or doing research with clinical and healthcare applications/relevance, are eligible to apply.
    2. Applicants who are working in human clinical research, including epidemiologists, biostatisticians, and whose research is clinically relevant and has potential health impact, will be considered as exceptions on a case-by-case basis.
    3. Non-medically trained applicants conducting wet laboratory based research are not eligible.
    4. Applicants must possess a minimum academic qualification of a PhD or the equivalent training.
    5. Recipients of NMRC Human Capital Awards, Transition Award and NMRC Research Training Fellowship are eligible to apply.
  3. A*STAR CS scholar from the National Science Scholarship (NSS) (MBBS-PhD) or NSS (MD-PhD) schemes and who fulfil the following may apply:
    1. hold primary appointments in Academic Medical Centres (AMCs), public health institutions (PHIs) or medical schools; or
    2. hold primary appointments in A*STAR but (with mutual agreement of A*STAR and the AMC/PHI/medical school) also hold a joint appointment in the AMC/PHI/medical school, provided that any such grant application is supported by the AMC/PHI/medical school.The institution/school should also consider if these A*STAR CS scholars are able to demonstrate that they can act as a bridge between A*STAR and the healthcare system.
    3. submit the grant application through AMCs/PHIs/medical schools as host institutions.
  4. For proposals involving patients, the clinical PI or co-I should be SMC registered; or should be able to demonstrate ability to access patients through SMC registered collaborators. For some CS-IRG-NIG proposals it is recognized that some studies may be pre-clinical and not require the PI to be SMC registered.
  5. Only one PI is allowed per application. The number of applications by an individual (as PI) is capped at 1 grant application per grant type in a grant call.

Additional eligibility criteria include:

(a)  Hold a primary appointment in a local public hospital/public health institutions/national specialty centre/public universities/Academic Medical Centres and salaried by the institution.

(b) Demonstrate relevant interest in research as evidenced by recent past work, including but not limited to clinical work, publications, participation in research studies etc.

(c) Have access to a laboratory or clinical research program that carries out research in Singapore.

(d)  Hold a minimum of 9 months employment with a local public institution. Upon award, the PI must agree to fulfill at least 6 months of residency in Singapore for each calendar year over the duration of the grant award. 

(e) No outstanding reports from previous BMRC, NMRC grants and other national grants.

Funding Quantum:

The CS-IRG-NIG will provide a funding quantum of up to S$260,000  (inclusive of up to 30% indirect costs^) for up to 2 years.  Projects involving prospective patient/subject recruitment may apply for a funding duration of up to 3 years, subject to the same funding quantum.

^Indirect costs is not applicable for research scholarship budget.

Grant Call Frequency:

There will be two grant calls per year (Jan and Jul). 

Submission:

It is mandatory for all applications to be submitted and endorsed by the Host Institution's Director of Research (DOR) online via IGMS by 1 August 2022, 5pm. We will not entertain any late submissions or submissions from individual applicants without endorsement from the Host Institution.

Please download the CS-IRG-NIG Guide and Application Form for more information. 

Review Panel:

The composition of the CS-IRG/NIG Review Panel 2022-2024 is listed in the table below.

 S/N Name Designation
 1 Prof Thomas COFFMAN
(Co-Chair)

Dean, Duke-NUS Medical School
Professor, Cardiovascular & Metabolic Disorders Programme, Duke-NUS
James R. Clapp Professor, Medicine, Duke University Medical Center

 2 Prof Joseph Sung
(Co-Chair)
Distinguished University Professor

Dean, Lee Kong Chian School of Medicine
Senior Vice President (Health and Life Sciences)
Nanyang Technological University, Singapore

 3 Prof John CHAMBERS

Professor, Cardiovascular Epidemiology, Lee Kong Chian School of Medicine, Nanyang Technological University
President’s Chair in Cardiovascular Epidemiology

 4 Prof Boon Cher GOH Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore

Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore
Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

 5 Prof Ecosse LAMOUREUX Professor, SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Programme
Director of the Population Research and Clinical Epidemiology platform, Singapore Eye Research Institute
 6 A/Prof Nagaendran KANDIAH Director, Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine
Co-Director, Neuroscience and Mental Health Programme, NTU
 7 Prof Soo Chin LEE  Head & Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore

Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

 8 Prof Gopal LYER Head & Senior Consultant, Division of Surgery & Surgical Oncology, National Cancer Centre Singapore

Senior Consultant, SingHealth Duke-NUS Head and Neck Centre
Head & Senior Consultant, Head & Neck Surgery, Singapore General Hospital

 9 A/Prof Oon Tek NG Senior Consultant, Department of Infectious Diseases, TTSH and NCID

Deputy Head, Infectious Disease Research Laboratory, NCID
Associate Professor, Lee Kong Chian School of Medicine, NTU

 10 Prof Eng Eong OOI Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School

Professor, Department of Microbiology & Immunology, National University of Singapore
Professor, Saw Swee Hock School of Public Health, National University of Singapore
Co-Director, Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (ViREMiCS)

 11 Prof Mark RICHARDS Director Cardiovascular Research Institute (CVRI)
Deputy Director National University Heart Centre Singapore (NUHCS) 
 12 A/Prof Vijay K SHARMA Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore
Senior Consultant, Division of Neurology, Department of Medicine, National University Hospital
 13 Prof Yik Ying TEO Dean, Saw Swee Hock School of Public Health, NUS
Department of Statistics and Applied Probability, Faculty of Science, NUS
 14 Prof David VIRSHUP  onorary Joint Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NU
Program Director for Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School
 15 Prof Ian CAMPBELL Co-Head, Women’s Cancer Program, Peter MacCallum Cancer Centre
Head, Cancer Genetics Laboratory, Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia
Principal Investigator, Lifepool
 16 Prof Bernard MY CHEUNG Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics
Chief, Division of Clinical Pharmacology & Therapeutics, Department of Medicine, University of Hong Kong, HK
 17 Prof Mark COOPER Head of Department of Diabetes, Central Clinical School, Monash University
 18 Dr Masaru KATOH Doctorate, National Cancer Centre, Tokyo, Japan
 19 Prof Anskar LEUNG Professor, Chair of Haematology

Li Shu Fan Medical Foundation Professor in Haematology
Department of Medicine, School of Clinical Medicine
LKS Faculty of Medicine
University of Hong Kong

 20 Prof Rajiv KHANNA Senior Scientist, QIMR Berghofer Medical Research Institute

Honorary Professor, University of Queensland and Griffith University, Brisbane, Australia.

 21 Prof Thomas KLIMKAIT  Project Leader, University of Basel, Switzerland
 22  

Prof Matthias OCKER

Faculty member and adjunct professor of experimental medicine, Charité University Medicine Berlin

Department of Hematology, Oncology and Cancer Immunology (CCM)
Vice President of Translational Medicine, Anji Pharma

 23 Prof Calvin Chi Pui PANG S.H. Ho Research Professor of Visual Sciences, Chinese University of Hong Kong, HK

Director, Shantou University/Chinese University of Hong Kong Joint Shantou International Eye Center, HK

 24 Prof Kyong Soo PARK Director, Center for Precision Medicine, Seoul National University, KR
 25 Prof Hai QI Professor, School of Medicine, Tsinghua University
 26 Prof Takeshi SAKURAI Professor of Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine
Adjunct faculty of Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons

Applicants are not allowed to approach any of the panel members to discuss or solicit information related to their application review or funding decisions. NMRC may impose a suspension and/or debarment on such applicants.